ERCC1 is not expressed in hepatocellular cancer: A Turkish Oncology Group, Gastrointestinal Oncology Subgroup study

Turhal N. S., Bas E., Er O., Aliustaoglu M., Seber S., Dane F., ...Daha Fazla

JOURNAL OF BUON, cilt.15, sa.4, ss.794-796, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 4
  • Basım Tarihi: 2010
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.794-796
  • Anahtar Kelimeler: ERCC1, hepatocellular cancer, immunohistochemistry, EXCISION-REPAIR GENES, LUNG-CANCER, CARCINOMA, CHEMOTHERAPY, CISPLATIN, RISK
  • Marmara Üniversitesi Adresli: Evet

Özet

Purpose: Hepatocellular cancer (HCC) is a common malignancy with a high mortality rate. Existence of excisional repair cross complementation1 (ERCC1) is implicated in resistance to cisplatin treatment. Expression of ERCC1 in HCC is not known. In this study we aimed to find out whether a subset of HCC patients can be identified to benefit from cisplatin.